This novel platform technology enhances diabetes management by providing continuous glucose monitoring for diabetes patients.

**Background**

Diabetes affects 25 million Americans and some 200 million people worldwide. Diabetes greatly increases risk of heart disease, stroke, infection, and pregnancy complications. The current standard of care for glucose management is the fingerpick assay. This results in notoriously low patient compliance, especially among children and elderly patients who have difficulty obtaining the blood samples. The development of a non-invasive, continuous monitor and novel analysis techniques would ultimately revolutionize diabetes management by: allowing long term, non-invasive blood-glucose monitoring, resulting in fewer pathological complications; dramatically increasing patient compliance through an automated.

**Technology**

The GlucoREAD Patch developed by Dr. Mujica-Parodi in Stony Brook University's Department of Biomedical Engineering is a non-invasive ambulatory biosensor that will permit individuals with Type 1 and Type 2 continuously monitor their glucose, insulin and hormones for an extended period of time. Moreover, this novel platform technology permits analysis of change over time leading to a much more sensitive and individualized approach. Because GlucoREAD technology uses scatter of ordinary light through the skin, rather than needles, it provides a painless alternative to blood pricks for feedback on glucose levels thereby improving compliance and quality of life for diabetics, particularly children.

**Patent number/Publication:**

- PCT/US2013/054343

**Advantages**

- Non-invasive, accurate measurements of blood glucose levels, continuous monitoring, ease of use

**Applications**

- Diabetes
- Diagnostics

**Valery Matthys, PhD**

Licensing Specialist

Office of Technology Licensing and Industry Relations

N5002 Melville Library

Stony Brook University

Stony Brook, NY 11794-3369

631-632-6561

Valery.matthys@stonybrook.edu

www.stonybrook.edu/research/otlir